Re: Fw: Review of Alizect trials (Adagio)

[mschild <mmoo@xxxxxxxxxxx>]

> " Uncertainty is not a satisfying result. The results of this study1 and
> TEMPO2 will certainly lead some clinicians to use rasagiline for its known
> symptomatic benefi t and the possibility of slowing PD disease progression.
> Other clinicians will use established PD therapies (eg, levodopa) that also
> have some hint of slowing PD progression and are less costly. The
> uncertainty should be settled by further investigation of both the 1 mg
> dose and the 2 mg dose, learning from the lessons of previous studies.
> Although the investigators should be congratulated for a considerable
> research accomplishment, the implications for patient care remain
> uncertain."


A convoluted way to say they don´t know if it is neuroprotective and that 
there are cheaper drugs doing the same thing;-)

It has been OK´ed in Europe but some countries hesitate still to reimburse it 
because it doesn´t present anything new, so I am told.

maryse

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:listserv@xxxxxxxxxxxxxxxxxxxx
In the body of the message put: signoff parkinsn